Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
NMRA Neumora Therapeutics	$1.42 -2.4%	$0.82	$0.61 ▼ $17.19	$225.64M	2.75	1.56 million shs	580,097 shs
PGEN Precigen	$1.93 +4.1%	$1.48	$0.65 ▼ $2.17	$568.22M	1.78	1.47 million shs	345,430 shs
SAGE Sage Therapeutics	$9.17 -0.1%	$7.78	$4.62 ▼ $13.47	$573.92M	0.29	1.33 million shs	177,115 shs
ZVRA Zevra Therapeutics	$12.64 -1.2%	$9.26	$5.45 ▼ $13.16	$690.06M	1.97	725,420 shs	348,483 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
NMRA Neumora Therapeutics	+14.17%	+60.81%	+71.70%	+130.16%	-87.51%
PGEN Precigen	-5.13%	+8.82%	+21.71%	+35.04%	+12.46%
SAGE Sage Therapeutics	+0.22%	+0.11%	+36.87%	+24.42%	-22.29%
ZVRA Zevra Therapeutics	0.00%	+10.74%	+40.09%	+81.42%	+105.30%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
NMRA Neumora Therapeutics	2.6733 of 5 stars	3.1	3.0	0.0	1.7	2.5	1.3
PGEN Precigen	4.0459 of 5 stars	3.5	0.0	4.7	4.0	1.7	0.6
SAGE Sage Therapeutics	3.4162 of 5 stars	2.0	4.0	4.1	1.8	1.7	0.6
ZVRA Zevra Therapeutics	3.0532 of 5 stars	3.6	5.0	0.0	3.2	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
NMRA Neumora Therapeutics	2.22	Hold	$7.14	404.80% Upside
PGEN Precigen	3.00	Buy	$6.00	211.69% Upside
SAGE Sage Therapeutics	1.94	Reduce	$8.75	-4.56% Downside
ZVRA Zevra Therapeutics	3.11	Buy	$23.71	87.61% Upside

Current Analyst Ratings Breakdown

Latest NMRA, SAGE, PGEN, and ZVRA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/16/2025	NMRA Neumora Therapeutics	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$4.00 ➝ $5.00
7/10/2025	ZVRA Zevra Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$25.00 ➝ $29.00
7/8/2025	SAGE Sage Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$12.00 ➝ $9.20
7/2/2025	ZVRA Zevra Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$26.00
6/20/2025	SAGE Sage Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$7.00 ➝ $9.00
6/17/2025	SAGE Sage Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$9.00 ➝ $8.50
6/17/2025	SAGE Sage Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Hold ➝ Hold	$8.00 ➝ $9.00
6/17/2025	SAGE Sage Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$12.00
6/17/2025	SAGE Sage Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$8.00 ➝ $8.50
6/16/2025	SAGE Sage Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
6/12/2025	PGEN Precigen	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$6.00

(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
NMRA Neumora Therapeutics	N/A	N/A	N/A	N/A	$1.78 per share	N/A
PGEN Precigen	$3.92M	144.95	N/A	N/A	$0.13 per share	14.81
SAGE Sage Therapeutics	$47.40M	12.11	N/A	N/A	$7.60 per share	1.21
ZVRA Zevra Therapeutics	$23.61M	29.27	N/A	N/A	$0.74 per share	17.08

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
NMRA Neumora Therapeutics	-$243.79M	-$1.61	N/A	N/A	N/A	N/A	-84.79%	-77.57%	8/5/2025 (Estimated)
PGEN Precigen	-$126.24M	-$0.56	N/A	N/A	N/A	-3,728.87%	-279.20%	-79.74%	8/13/2025 (Estimated)
SAGE Sage Therapeutics	-$400.67M	-$5.80	N/A	N/A	N/A	-747.63%	-68.99%	-60.67%	7/30/2025 (Estimated)
ZVRA Zevra Therapeutics	-$105.51M	-$1.90	N/A	63.20	N/A	-226.78%	-201.05%	-53.55%	8/12/2025 (Estimated)

Latest NMRA, SAGE, PGEN, and ZVRA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	PGEN Precigen	-$0.14	N/A	N/A	N/A	$0.67 million	N/A
8/12/2025	Q2 2025	ZVRA Zevra Therapeutics	$0.65	N/A	N/A	N/A	$22.49 million	N/A
8/5/2025	Q2 2025	NMRA Neumora Therapeutics	-$0.38	N/A	N/A	N/A	N/A	N/A
7/30/2025	Q2 2025	SAGE Sage Therapeutics	-$0.96	N/A	N/A	N/A	$16.69 million	N/A
5/14/2025	Q1 2025	PGEN Precigen	-$0.08	-$0.07	+$0.01	-$0.18	$0.50 million	$1.34 million
5/13/2025	Q1 2025	ZVRA Zevra Therapeutics	-$0.21	-$0.06	+$0.15	-$0.06	$16.96 million	$20.40 million
5/12/2025	Q1 2025	NMRA Neumora Therapeutics	-$0.40	-$0.42	-$0.02	-$0.42	N/A	N/A
4/29/2025	Q1 2025	SAGE Sage Therapeutics	-$0.99	-$1.01	-$0.02	-$1.01	$14.12 million	$14.06 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
NMRA Neumora Therapeutics	N/A	N/A	N/A	N/A	N/A
PGEN Precigen	N/A	N/A	N/A	N/A	N/A
SAGE Sage Therapeutics	N/A	N/A	N/A	N/A	N/A
ZVRA Zevra Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
NMRA Neumora Therapeutics	N/A	8.98	8.98
PGEN Precigen	N/A	3.53	3.53
SAGE Sage Therapeutics	N/A	9.13	9.13
ZVRA Zevra Therapeutics	1.46	3.02	2.93

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
NMRA Neumora Therapeutics	47.65%
PGEN Precigen	33.51%
SAGE Sage Therapeutics	99.22%
ZVRA Zevra Therapeutics	35.03%

Insider Ownership

Company	Insider Ownership
NMRA Neumora Therapeutics	26.80%
PGEN Precigen	47.10%
SAGE Sage Therapeutics	5.50%
ZVRA Zevra Therapeutics	2.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
NMRA Neumora Therapeutics	108	161.75 million	118.40 million	Optionable
PGEN Precigen	190	295.18 million	156.15 million	Optionable
SAGE Sage Therapeutics	690	62.62 million	59.18 million	Optionable
ZVRA Zevra Therapeutics	20	54.68 million	53.37 million	Optionable

NMRA, SAGE, PGEN, and ZVRA Headlines

Recent News About These Companies

5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats

1 hour ago | zacks.com

Zevra Therapeutics Announces Open Label Extension Data Showing Sustained Long-Term Efficacy of MIPLYFFA for the Treatment of NPC Published in the Journal of Molecular Genetics and Metabolism

3 hours ago | globenewswire.com

Zevra Therapeutics Publishes Long-Term Efficacy and Safety Results for MIPLYFFA in Niemann-Pick Disease Type C

4 hours ago | quiverquant.comQ

Zevra Therapeutics (NASDAQ:ZVRA) Reaches New 12-Month High - Time to Buy?

5 hours ago | marketbeat.com

Q2 EPS Forecast for Zevra Therapeutics Raised by Analyst

5 hours ago | marketbeat.com

Wall Street Analysts Predict an 86.55% Upside in Zevra Therapeutics (ZVRA): Here's What You Should Know

July 15 at 12:40 PM | finance.yahoo.com

Wall Street Analysts Predict an 86.55% Upside in Zevra Therapeutics (ZVRA): Here's What You Should Know

July 15 at 10:56 AM | zacks.com

Here's Why 'Trend' Investors Would Love Betting on Zevra Therapeutics (ZVRA)

July 15 at 9:50 AM | zacks.com

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Rating of "Buy" by Brokerages

July 15 at 2:03 AM | americanbankingnews.com

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives Consensus Rating of "Buy" from Analysts

July 15 at 2:29 AM | marketbeat.com

Zevra Therapeutics (NASDAQ:ZVRA) Raised to Strong-Buy at Wall Street Zen

July 14 at 2:23 AM | americanbankingnews.com

Cantor Fitzgerald Issues Positive Outlook for ZVRA Earnings

July 14 at 2:40 AM | marketbeat.com

Zevra Therapeutics (NASDAQ:ZVRA) Price Target Raised to $29.00

July 13 at 2:01 AM | americanbankingnews.com

Zevra Therapeutics (NASDAQ:ZVRA) Upgraded to Strong-Buy at Wall Street Zen

July 12, 2025 | marketbeat.com

Zevra Therapeutics Announces MIPLYFFA® (arimoclomol) Featured in Presentations at the National Niemann Pick Disease Foundation Conference

July 11, 2025 | finance.yahoo.com

Zevra Therapeutics Showcases MIPLYFFA® Data at National Niemann Pick Disease Foundation Conference

July 11, 2025 | quiverquant.comQ

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Shares Sold by Stratos Wealth Partners LTD.

July 11, 2025 | marketbeat.com

Zevra Therapeutics (NASDAQ:ZVRA) Price Target Raised to $29.00 at Cantor Fitzgerald

July 10, 2025 | marketbeat.com

Zevra Therapeutics (NASDAQ:ZVRA) Reaches New 1-Year High - Here's What Happened

July 10, 2025 | marketbeat.com

Noteworthy Monday Option Activity: ZVRA, U, WNS | Nasdaq

July 8, 2025 | nasdaq.com

Zevra Therapeutics (NASDAQ:ZVRA) Sees Unusually-High Trading Volume - What's Next?

July 7, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NMRA, SAGE, PGEN, and ZVRA Company Descriptions

Neumora Therapeutics NASDAQ:NMRA

$1.42 -0.04 (-2.41%)

As of 10:52 AM Eastern

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

Precigen NASDAQ:PGEN

$1.92 +0.08 (+4.05%)

As of 10:53 AM Eastern

Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

Sage Therapeutics NASDAQ:SAGE

$9.16 -0.01 (-0.05%)

As of 10:53 AM Eastern

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Zevra Therapeutics NASDAQ:ZVRA

$12.64 -0.15 (-1.17%)

As of 10:53 AM Eastern

Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time